GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: LON:GWP
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: GBX 810.64
- 200 Day Moving Avg: GBX 650.91
- 52 Week Range: GBX 211 - GBX 950
- Trailing P/E Ratio: N/A
- P/E Growth: 0.000
- Average Volume: 811,003 shs.
Frequently Asked Questions for GW Pharmaceuticals plc (LON:GWP)
What is GW Pharmaceuticals plc's stock symbol?
GW Pharmaceuticals plc trades on the London Stock Exchange (LON) under the ticker symbol "GWP."
Where is GW Pharmaceuticals plc's stock going? Where will GW Pharmaceuticals plc's stock price be in 2017?
1 analysts have issued 1-year target prices for GW Pharmaceuticals plc's stock. Their predictions range from GBX 835 to GBX 835. On average, they anticipate GW Pharmaceuticals plc's share price to reach GBX 835 in the next twelve months. View Analyst Ratings for GW Pharmaceuticals plc.
Who are some of GW Pharmaceuticals plc's key competitors?
Some companies that are related to GW Pharmaceuticals plc include Partnership Assurance Group PLC (PA), Royal Dutch Shell Plc (RDSB), HSBC Holdings plc (HSBA), Unilever plc (ULVR), British American Tobacco plc (BATS), BP plc (BP), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), BHP Billiton plc (BLT), Vodafone Group plc (VOD), Diageo plc (DGE), Rio Tinto plc (RIO), Lloyds Banking Group PLC (LLOY), Barclays PLC (BARC), Reckitt Benckiser Group Plc (RB), Prudential plc (PRU), Shire PLC (SHP) and Glencore PLC (GLEN).
How do I buy GW Pharmaceuticals plc stock?
Shares of GW Pharmaceuticals plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
How much does a share of GW Pharmaceuticals plc stock cost?
One share of GW Pharmaceuticals plc stock can currently be purchased for approximately GBX 716.60.
Consensus Ratings for GW Pharmaceuticals plc (LON:GWP) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||1 Hold Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||GBX 835|
Analysts' Ratings History for GW Pharmaceuticals plc (LON:GWP)
(Data available from 5/24/2015 forward)
|9/27/2016||Numis Securities Ltd||Reiterated Rating||Hold||GBX 835|
|3/14/2016||Peel Hunt||Reiterated Rating||Under Review|
Earnings History for GW Pharmaceuticals plc (LON:GWP)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for GW Pharmaceuticals plc (LON:GWP)
Current Year EPS Consensus Estimate: $-31.300 EPS
Dividend History for GW Pharmaceuticals plc (LON:GWP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for GW Pharmaceuticals plc (LON:GWP)Insider Trades by Quarter for GW Pharmaceuticals plc (LON:GWP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/1/2016||Tom Lynch||Insider||Sell||2,074||GBX 790||£16,384.60|
|10/28/2016||Geoffrey Guy||Insider||Sell||31,682||GBX 790||£250,287.80|
|10/27/2016||Geoffrey Guy||Insider||Sell||138,318||GBX 804||£1,112,076.72|
|10/26/2016||Geoffrey Guy||Insider||Sell||130,000||GBX 808||£1,050,400|
|10/25/2016||Geoffrey Guy||Insider||Sell||125,000||GBX 809||£1,011,250|
|10/24/2016||Geoffrey Guy||Insider||Sell||68,900||GBX 824||£567,736|
|5/10/2016||Lynch ,Tom||Insider||Sell||50,000||GBX 441||£220,500|
|12/10/2015||Lynch ,Tom||Insider||Sell||4,270||GBX 451||£19,257.70|
|6/12/2015||James Noble||Insider||Sell||20,000||GBX 636||£127,200|
|6/11/2015||Stephen Wright||Insider||Sell||170,400||GBX 641||£1,092,264|
|2/9/2015||Christopher John Tovey||Insider||Sell||10,000||GBX 404.20||£40,420|
Headline Trends for GW Pharmaceuticals plc (LON:GWP)
Latest Headlines for GW Pharmaceuticals plc (LON:GWP)
GW Pharmaceuticals plc (GWP) Chart for Wednesday, May, 24, 2017